Search results for "blind"

showing 10 items of 1063 documents

Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two ra…

2020

Thyroid eye disease manifests inflammation and treatment-resistant proptosis and diplopia. Teprotumumab, an insulin-like growth factor-1 receptor inhibiting monoclonal antibody, was approved in the USA on Jan 21, 2020, on the basis of two randomised trials. In this analysis we evaluated the short-term and long-term aggregate response to teprotumumab from the two trials, focusing on proptosis and diplopia.We analysed integrated outcomes and follow-up data from two randomised, double-masked, placebo-controlled, multicentre, trials done at a total of 28 academic referral tertiary specialised centres offering joint thyroid eye clinics, or orbital clinics or practices, or both, in Europe and the…

AdultData AnalysisMalemedicine.medical_specialtyEndocrinology Diabetes and MetabolismEye diseasePopulation030209 endocrinology & metabolismAntibodies Monoclonal HumanizedPlaceboSeverity of Illness Indexlaw.inventionPlacebos03 medical and health sciences0302 clinical medicineEndocrinologyDouble-Blind MethodRandomized controlled triallawInternal medicineSeverity of illnessInternal MedicinemedicineHumans030212 general & internal medicineeducationAgedDiplopiaeducation.field_of_studybusiness.industryThyroidMiddle Agedmedicine.diseaseUnited Stateseye diseasesEuropeGraves OphthalmopathyTreatment Outcomemedicine.anatomical_structureFemalemedicine.symptombusinessOff TreatmentFollow-Up StudiesThe Lancet Diabetes & Endocrinology
researchProduct

Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants

2003

Abstract A live attenuated human rotavirus (HRV) vaccine, strain RIX4414, was tested sequentially in adults, previously infected toddlers, and previously uninfected infants. A single dose was given to adults and toddlers and found well tolerated. Next, a dose ranging (three different viral concentrations) safety and immunogenicity study was conducted in rotavirus IgA antibody negative infants (N=192), who received two doses of RIX4414 vaccine or placebo at 2 and 4 months of age. No side effects were seen after vaccination. Specifically, administration of RIX4414 vaccine was not temporally associated with fever, diarrhea, or increase in liver transaminases. Rotavirus IgA seroconversion range…

AdultDiarrheaMaleAdolescentDose-Response Relationship ImmunologicReoviridaeVaccines Attenuatedmedicine.disease_causeRotavirus InfectionsVirusFecesDouble-Blind MethodLiver Function TestsRotavirusmedicineHumansCloning MolecularSeroconversionGeneral VeterinaryGeneral Immunology and Microbiologybiologybusiness.industryImmunogenicityRotavirus VaccinesPublic Health Environmental and Occupational HealthInfantbiology.organism_classificationVirologyImmunoglobulin AVaccinationTiterDiarrheaInfectious DiseasesChild PreschoolImmunologyMolecular MedicineFemalemedicine.symptombusinessVaccine
researchProduct

Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-versus-Host Disease

2007

Study Objective. To analyze the pharmacokinetics of posaconazole administered as prophylaxis for invasive fungal infections in recipients of hematopoietic stem cell transplants (HSCTs) who have graft-versus-host disease (GVHD). Design. Pharmacokinetic analysis in a subset of posaconazole-treated patients from a large, multicenter, phase III, randomized, double-blind, double-dummy, parallel-group trial that compared posaconazole with fluconazole. Setting. Ninety international medical centers. Patients. The subset of patients comprised 246 HSCT recipients for whom pharmacokinetic data were available. Intervention. All patients received posaconazole 200 mg oral suspension 3 times/day for a max…

AdultDiarrheaMalemedicine.medical_specialtyPosaconazoleAntifungal AgentsAdolescentCmaxGraft vs Host DiseaseOpportunistic InfectionsGastroenterologySex FactorsDouble-Blind MethodPharmacokineticsOral administrationInternal medicinemedicineHumansTransplantation HomologousPharmacology (medical)MycosisAgedbusiness.industryBody WeightRacial GroupsAge FactorsHematopoietic Stem Cell TransplantationMiddle AgedTriazolesmedicine.diseaseSurgeryTransplantationGraft-versus-host diseaseMycosesAcute DiseaseChronic DiseaseFemalebusinessFluconazolemedicine.drugPharmacotherapy
researchProduct

Caffeine Increases Strength and Power Performance in Resistance-trained Females During Early Follicular Phase

2020

The effects of 4 mg·kg−1caffeine ingestion on strength and power were investigated for the first time, in resistance-trained females during the early follicular phase utilizing a randomized, double-blind, placebo-controlled, crossover design. Fifteen females (29.8 ± 4.0 years, 63.8 ± 5.5 kg [mean ± SD]) ingested caffeine or placebo 60 minutes before completing a test battery separated by 72 hours. One-repetition maximum (1RM), repetitions to failure (RTF) at 60% of 1RM, was assessed in the squat and bench press. Maximal voluntary contraction torque (MVC) and rate of force development (RFD) were measured during isometric knee extensions, while utilizing interpolated twitch technique to measu…

AdultEarly follicular phaseWeight LiftingPhysical ExertionPhysical Therapy Sports Therapy and RehabilitationSquatStrength performancesIsometric exercisePerformance-Enhancing SubstancesPlyometric ExercisePlaceboMuscular activation levelsBench pressBeverageschemistry.chemical_compoundDouble-Blind MethodFemale athletesCaffeineIsometric ContractionIngestionMedicineHumansOrthopedics and Sports MedicineKneeMuscle StrengthCaffeine supplementationsCross-Over Studiesbusiness.industryResistance TrainingMyalgiaVDP::Medisinske Fag: 700::Idrettsmedisinske fag: 850Crossover studychemistryFollicular PhaseMuscular endurancesAnesthesiaFemalePerceptionPower performancesCaffeinebusiness
researchProduct

IGF-I, IgA, and IgG responses to bovine colostrum supplementation during training.

2002

This study examined the effect of bovine colostrum (Dynamic colostrum) supplementation on blood and saliva variables ( study 1) and the absorption of orally administered human recombinant insulin-like growth factor (IGF)-I (rhIGF-I) labeled with 123I (123I-rhIGF-I) ( study 2). In study 1, adult male and female athletes were randomly assigned in a double-blind fashion to either an experimental (Dynamic; n = 19) or a control (Placebo; n = 11) group. The former consumed daily 20 g of Dynamic supplement, and the latter 20 g of maltodextrin during a 2-wk training period. After bovine colostrum supplementation, significant increases were noticed in serum IGF-I ( P < 0.01) and saliva IgA ( P &…

AdultElectrophoresisMaleSalivamedicine.medical_specialtyPhysiologyCausticsAnimal originlaw.inventionReceptor IGF Type 1Iodine RadioisotopesDouble-Blind MethodlawPhysiology (medical)Internal medicinemedicineAnimalsHumansInsulin-Like Growth Factor ITrichloroacetic AcidSalivabusiness.industryColostrumImmunoglobulin AEndocrinologyNutrition AssessmentPhysical performancePhysical FitnessImmunoglobulin GDietary SupplementsRecombinant DNAColostrumCattleFemalebusinessJournal of applied physiology (Bethesda, Md. : 1985)
researchProduct

Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma

2015

SummaryIntroductionOnce-daily tiotropium Respimat® 5 μg is an efficacious add-on therapy to inhaled corticosteroids (ICS) with or without long-acting β2-agonists in patients with symptomatic asthma. The objective of this study was to investigate whether the dosing regimen of tiotropium (once- versus twice-daily), delivered via the Respimat® SoftMist™ inhaler, affected 24-h bronchodilator efficacy and safety versus placebo Respimat® in patients with asthma who were symptomatic despite medium-dose ICS therapy.MethodsA randomised, double-blind, placebo-controlled, crossover study with 4-week treatment periods of tiotropium 5 μg (once-daily, evening) and 2.5 μg (twice-daily, morning and evening…

AdultEstoniaMalePulmonary and Respiratory MedicineVital capacityRespimatEveningAdolescentmedicine.drug_classPlaceboDouble-Blind MethodRisk FactorsAnticholinergic drugForced Expiratory VolumeGermanyBronchodilatorAdministration InhalationmedicineHumansDosingDosing regimenTiotropium BromideAgedCzech RepublicAsthmaLong-acting bronchodilatorCross-Over StudiesDose-Response Relationship Drugbusiness.industryTiotropiumInhalerMiddle Agedmedicine.diseaseLatviaAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeBronchodilator efficacyAustriaAnesthesiaFemalebusinessRespiratory Medicine
researchProduct

The Effectiveness Of Radial Extracorporeal Shock Wave Therapy In Patients With Chronic Low Back Pain: A Prospective, Randomized, Single-Blinded Pilot…

2019

Karolina Walewicz,1 Jakub Taradaj,2,3 Katarzyna Rajfur,1 Kuba Ptaszkowski,4 Michał Tomasz Kuszewski,2 Mirosław Sopel,5 Robert Dymarek5 1Faculty of Physiotherapy, Opole Medical School, Opole, Poland; 2Institute of Physiotherapy and Health Sciences, Academy of Physical Education, Katowice, Poland; 3College of Rehabilitation Sciences, University of Manitoba, Winnipeg, MB, Canada; 4Department of Physiotherapy, Wroclaw Medical University, Wroclaw, Poland; 5Department of Nervous System Diseases, Wroclaw Medical University, Wroclaw, PolandCorrespondence: Robert DymarekDepartment of Nervous System Diseases, Faculty of Health Sciences, Wroclaw Medical University, Bartla 5, Wroclaw 51-618, PolandTe…

AdultExtracorporeal Shockwave TherapyMaleExtracorporeal shock wave therapyVisual analogue scalePilot Projects03 medical and health sciences0302 clinical medicineHumansPain ManagementMedicinephysical therapySingle-Blind MethodIn patientProspective Studies030212 general & internal medicineOriginal ResearchPain Measurementfunctional statebusiness.industryESWTshock wavesGeneral MedicinePain scaleMiddle AgedLow back painChronic low back painOswestry Disability IndexTreatment OutcomeAnesthesiaClinical Interventions in AgingHomogeneous groupFemaleGeriatrics and Gerontologymedicine.symptombusinessLow Back Pain030217 neurology & neurosurgeryClinical Interventions in Aging
researchProduct

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures

2022

The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32-56) years were included. During the 1-year study period, sustained se…

AdultFreedomfocal seizuresEpilepsiesSettore MED/26Double-Blind MethodDrug Therapyantiseizure medication; brivaracetam; focal seizures; seizure freedom; sodium channel blockers; Adult; Double-Blind Method; Drug Therapy Combination; Freedom; Humans; Middle Aged; Pyrrolidinones; Seizures; Treatment Outcome; Anticonvulsants; Epilepsies PartialSeizuresseizure freedomHumansanti-seizure medication; focal seizures; epilepsyantiseizure medicationbrivaracetamanti-seizure medicationMiddle AgedPyrrolidinonesTreatment OutcomeNeurologysodium channel blockersCombinationepilepsyDrug Therapy CombinationAnticonvulsantsNeurology (clinical)Epilepsies PartialPartial
researchProduct

Multicenter, double-blind, randomized, intraindividual crossover comparison of gadobenate dimeglumine and gadopentetate dimeglumine for Breast MR ima…

2011

To intraindividually compare 0.1 mmol/kg doses of gadobenate dimeglumine and gadopentetate dimeglumine for contrast material-enhanced breast magnetic resonance (MR) imaging by using a prospective, multicenter double-blind, randomized protocol.Institutional review board approval and patient informed consent were obtained. One hundred sixty-two women (mean age, 52.8 years ± 12.3 [standard deviation]) enrolled at 17 sites in Europe and China between July 2007 and May 2009 underwent at least one breast MR imaging examination at 1.5 T by using three-dimensional spoiled gradient-echo sequences. Of these, 151 women received both contrast agents in randomized order in otherwise identical examinatio…

AdultGadolinium DTPAChinaContrast MediaBreast NeoplasmsSensitivity and Specificitylaw.inventionDouble blindbreast neoplasm contrast media MRIBreast cancerMegluminebreast neoplasmRandomized controlled trialDouble-Blind MethodlawPredictive Value of TestsImage Interpretation Computer-AssistedmedicineOrganometallic CompoundsHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyGADOBENATE DIMEGLUMINEAgedAged 80 and overChi-Square DistributionCross-Over Studiesbusiness.industryMiddle Agedmedicine.diseaseMr imagingCrossover studyMagnetic Resonance ImagingEuropeFemaleBreast diseaseNuclear medicinebusinessMRIRadiology
researchProduct

Tacrolimus Monotherapy Without Steroids After Liver Transplantation – A Prospective Randomized Double-Blinded Placebo-Controlled Trial

2007

Early steroid withdrawal after liver transplantation (LT) is desirable in order to reduce steroid side effects. Between February 2000 and August 2004, 110 patients after LT were included in this prospective, randomized, double-blind, placebo-controlled trial. Randomization was performed before LT. In all patients, tacrolimus was used without induction therapy. All patients received methylprednisolon for 14 days, thereafter a double-blinded medication containing either placebo (n = 56) or methylprednisolon (n = 54) for 6 months, which was completely stopped thereafter. End points were patient and graft survival, acute and chronic rejection, and incidence of steroid side effects during the fi…

AdultGraft RejectionMalemedicine.medical_specialtyTime FactorsRandomizationmedicine.drug_classmedicine.medical_treatmentPlacebo-controlled studyLiver transplantationPlaceboMethylprednisoloneGastroenterologyTacrolimuslaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialAdrenal Cortex HormoneslawInternal medicinemedicineHumansImmunology and AllergyPharmacology (medical)Antibacterial agentTransplantationbusiness.industryMiddle AgedTacrolimusLiver TransplantationSurgeryCorticosteroidFemaleSafetybusinessImmunosuppressive AgentsFollow-Up StudiesAmerican Journal of Transplantation
researchProduct